To summarize, the present study suggests that changes in cytokine levels (IL-1β, IL-2, IL-6, and TNF-α) could serve as biomarkers for predicting treatment response and prognosis in patients with HNSCC. This evidence concerns the gene IL6 and head and neck squamous cell carcinoma.